In this mini-review, we summarize the current evidences on neoadjuvant targeted therapy for resectable EGFR-mutated NSCLC and focus on discussing potential clinical strategies of treating resectable EGFR-mutant patients by preoperative administration of EGFR-TKIs-based multimodality therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.